Skip to main content
. 2020 Jan 13;135(13):1049–1057. doi: 10.1182/blood.2019004218

Table 2.

Response to eculizumab therapy

Variable OR P
Log (sC5b-9) at TA-TMA diagnosis 0.28 .026
Log (sC5b-9 max) before starting eculizumab 0.15 .0014
rUPCR at TA-TMA diagnosis 0.76 .65
aGVHD diagnosed before TA-TMA* 0.96 .95
aGVHD diagnosed after TA-TMA*, 0.3 .16

The OR is from a univariate logistic regression model with response defined as a CR or a PR. An OR > 1 indicates that the variable corresponds to a decrease in the odds of a response.

aGVHD, acute GVHD.

*

Analysis excludes autologous HSCT recipients.

Analysis excludes those with aGVHD before TA-TMA.